RxDoctor Payments Data

Tonya Money, APRN

Family · Elizabethtown, KYNPI 1497847677

Payments from drug & device makers

$2,168in general payments, 2019–2025

Across 134 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$398
  • Pfizer$349
  • GSK$198
  • Lilly USA, LLC$141
  • Merz North America, Inc.$132
  • Novo Nordisk$132
  • plus $818 from 24 others

What the payments were for

  • Food & beverage$2,168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,168 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$33,633
Medicare patients
129
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide68$75,209
JanuviaSitagliptin Phosphate23$21,313
OzempicSemaglutide20$20,896
JardianceEmpagliflozin14$15,676
EliquisApixaban13$11,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,406
Pregabalin38$1,788
Aripiprazole15$1,658
SynthroidLevothyroxine Sodium24$1,495
Nebivolol Hcl15$1,410
Albuterol Sulfate HfaAlbuterol Sulfate42$1,201
Levothyroxine Sodium131$1,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,025
Atorvastatin Calcium155$1,001
Ondansetron OdtOndansetron42$976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$141$75,20968 claims
MerckJanuvia$68$21,31323 claims
Novo NordiskOzempic$132$20,89620 claims
PfizerEliquis$349$11,89213 claims
GSKTrelegy Ellipta$198$9,40615 claims
AbbVieSynthroid$398$1,49524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →